Michael Dickinson
MBBS, FRACP, FRCPA
Associate Professor; Head, Lymphoma Program
👥Biography 个人简介
Michael Dickinson is a lymphoma oncologist who has contributed to multiple pivotal clinical trials of novel agents in DLBCL including glofitamab, epcoritamab, liso-cel (TRANSCEND NHL), and tafasitamab-lenalidomide (L-MIND). He leads the Australian Lymphoma Alliance and has worked to improve access to CAR-T and bispecific therapies in the Asia-Pacific region. His research addresses real-world outcomes of novel DLBCL therapies, access barriers, and safety management including CRS. He is an active contributor to international DLBCL consensus guidelines.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Michael Dickinson 的研究动态
Follow Michael Dickinson's research updates
留下邮箱，当我们发布与 Michael Dickinson（Peter MacCallum Cancer Centre, University of Melbourne）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment